Article Open access 15 December 2021 Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours Article Open access 18 November 2021 Back...
Potential cytochrome P-450 (CYP) drug-drug interactions in adults with metastatic solid tumors and their effect on eligibility for Phase I clinical trials were characterized.This study included adult patients with metastatic solid tumors seen by a medical oncologist from January 2008 through July 2011...
population7. However, similar to other TKIs, the efficacy of mobocertinib is restricted by the structural heterogeneity of 20ins TKDs. Although a median duration of response (DOR) of 17.5 months demonstrates sustained clinical benefits in responding patients, an ORR of 28% is still below our ...
No additional dose limiting toxicities (DLT) were observed in Cohort A since the initial Phase 1a dose escalation.Clinical activity for IMA203 TCR-T monotherapy in Phase 1b Cohort A: IMA203 monotherapy demonstrates a high rate of deep objective responses with ongoing durabili...
1A-HBV indicates single-antigen hepatitis B virus vaccine; 3A-HBV, 3-antigen HBV; AE, adverse event; and SAE, serious AE. aIndividuals may have multiple reasons for exclusion. Figure 2. Seroprotection Rates and Serum Hepatitis B Surface Antibody (Anti-HB) Concentrations in Pooled 3-Antigen ...
RNA sequencing from evaluable pre-therapeutic tumor biopsies defined a signature of differentially expressed genes to be predictive of clinical outcome in ALZ-CHOP but not CHOP treated pts (n=33). Tumor microenvironment genes were prominent in determining response to ALZ. Tumors rich in B-cell ...
and 9% in patients homozygous for the wild-type allele. Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue Trodelvy based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with...
CD19.CAR transgene expression by flow cytometry ranged from 20% to 48% of CD3+ T cells and met the release criterion of ≥20% CAR expression (Figure 1A). Five CD19.CAR-VST lines were composed of predominantly CD8+ cells, whereas three were predominantly CD4+ cells (Figure 1B). The ...
ClinicalTrials数据库提供临床试验Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A的登记号NCT03520751,试验分期Phase 1/Phase 2以及申办者Nationwide Children's Hospital的信息,更过关于临床试验的其他信息查询就在戊戌数据美国临床试验数据库.
1a). Deficiencies in PCC lead to an accumulation of toxic metabolites, including propionyl-CoA and organic acids, such as 2-methylcitrate (2-MC) and 3-hydroxypropionate (3-HP)2,3. The birth prevalence of PA varies by country, affecting approximately 1 in 100,000 to 150,000 individuals in...